Back to School: How biopharma can reboot drug development. Access exclusive analysis here
The double-blind, international Phase II DreaMS trial in 407 patients aged 18-55 with RRMS showed that once-daily 0.05, 0.1 and 0.15 mg
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury